Several other brokerages also recently weighed in on PRAH. Robert W. Baird raised their price target on shares of PRA Health Sciences from $119.00 to $122.00 and gave the company an outperform rating in a research report on Thursday, February 28th. Wolfe Research assumed coverage on shares of PRA Health Sciences in a research report on Tuesday, April 2nd. They set a market perform rating for the company. SunTrust Banks raised their price target on shares of PRA Health Sciences to $120.00 and gave the company an average rating in a research report on Monday, March 4th. ValuEngine raised shares of PRA Health Sciences from a hold rating to a buy rating in a research report on Monday, February 4th. Finally, Mizuho set a $100.00 price target on shares of PRA Health Sciences and gave the company a hold rating in a research report on Friday, May 3rd. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $113.22.
Shares of PRAH opened at $89.05 on Wednesday. The company has a market cap of $5.85 billion, a P/E ratio of 22.66, a PEG ratio of 1.16 and a beta of 1.01. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 0.97. PRA Health Sciences has a twelve month low of $80.28 and a twelve month high of $121.98.
Hedge funds have recently modified their holdings of the stock. Cresset Asset Management LLC purchased a new stake in PRA Health Sciences in the first quarter worth approximately $25,000. Motco boosted its holdings in PRA Health Sciences by 937.0% in the first quarter. Motco now owns 280 shares of the medical research company’s stock worth $31,000 after purchasing an additional 253 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new stake in PRA Health Sciences in the first quarter worth approximately $37,000. Financial Gravity Wealth Inc. purchased a new stake in PRA Health Sciences in the first quarter worth approximately $53,000. Finally, Manchester Capital Management LLC purchased a new stake in PRA Health Sciences in the first quarter worth approximately $57,000. Institutional investors own 99.09% of the company’s stock.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Read More: What is the Fibonacci sequence?
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.